In the News

The current 71,600-square-foot operation will grow to 114,000 square feet and be completed in stages by the end of 2024, creating 200 new jobs over the next five years.

Much of the expansion involves adding to the business’ sample management and testing capacity to support new therapeutics, including vaccines and cell and gene therapy products.

The bulk of the expansion with this new facility will occur in liquid chromatography-mass spectrometry for drug discovery through to clinical testing.

New network will be available to the full range of sites that the business currently works with to deliver DCT studies for customers.

New network to support global investigators and research sites participating in decentralized clinical trials for pharmaceutical and biotech customers.

The ongoing expansion of our bioanalytical operations builds on the growth of our drug development expertise over nearly four decades.

State-of-the art bioanalytical lab in Richmond, Virginia, will support increasing demand across biopharma for consistent, high-quality laboratory services to accelerate drug development.

More than 150 leaders at global biotech and pharmaceutical organizations assessed the therapies in their pipelines, barriers to bringing drugs to market, innovations in pursuit and lingering effects of COVID-19.

The authors discuss how a more crowded space is presenting new challenges that must be addressed to improve efficiency.